Начало › Рак на гърдата › Мериленд › Baltimore
Клинични проучвания за Рак на гърдата в Baltimore, MD
47 проучвания за Рак на гърдата търсят участници в обекти в и около Baltimore (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Набиране на участнициФаза 3
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Набиране на участнициФаза 2
- Sidney Kimmel Comprehensive Cancer Center, Baltimore
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Набиране на участнициФаза 3
- Mercy Medical Center, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и още 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 2
- Johns Hopkins University, Baltimore
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Набиране на участнициФаза 2
- Maryland Proton Treatment Center, Baltimore
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Набиране на участнициФаза 3
- Maryland Proton Treatment Center, Baltimore
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Набиране на участнициФаза 3
- Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Набиране на участнициФаза 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Набиране на участнициФаза 3
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Annapolis · на 22 мили
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Набиране на участнициФаза 1
- United Theranostics, Glen Burnie · на 9 мили
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Набиране на участнициФаза 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Набиране на участнициФаза 3
- Saint Agnes Hospital, Clinical Research Center, Baltimore
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Набиране на участнициФаза 3
- Mercy Medical Center, Baltimore
- Ascension St. Agnes Hospital, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Набиране на участнициФаза 1/2
- Research Site, Baltimore
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Набиране на участнициФаза 1/2
- Maryland Oncology Hematology - Annapolis, Annapolis · на 22 мили
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Набиране на участнициФаза 3
- University of Maryland, Baltimore
- Velocity Clinical Research, Annapolis · на 22 мили
Cardiometabolic Screening Program
Набиране на участници
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Набиране на участнициФаза 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Набиране на участнициФаза 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Mercy Medical Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- и още 8
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Набиране на участнициФаза 2
- The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Набиране на участнициФаза 2/3
- Local Institution - 1035, Baltimore
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Набиране на участнициФаза 3
- Maryland Oncology Hematology, Annapolis · на 22 мили
E-Mindfulness Approaches for Living After Breast Cancer
Набиране на участнициФаза 3
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и още 7
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Набиране на участнициФаза 2
- The John Hopkins Hospital, Baltimore
EXoPERT EMERALD Clinical Study
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- John Hopkins University, Baltimore
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Набиране на участнициФаза 3
- Johns Hopkins Kimmel Cancer Center, Baltimore
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Набиране на участнициФаза 1
- Johns Hopkins University, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Набиране на участнициФаза 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · на 9 мили
- United Theranostics - Chesapeake, Glen Burnie · на 9 мили
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Набиране на участнициФаза 1
- United Theranostics, Glen Burnie · на 9 мили
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Набиране на участнициФаза 3
- Mfsmc-Hjwci, Baltimore
- Maryland Oncology Hematology P.A., Annapolis · на 22 мили
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Набиране на участнициФаза 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Saint Agnes Hospital, Baltimore
- и още 7
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · на 8 мили
- и още 1
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
Набиране на участници
- Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins, Baltimore
- Johns Hopkins Bayview, Baltimore
- Johns Hopkins Kimmel Cancer Center at Greenspring Station, Lutherville · на 9 мили
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
Набиране на участници
- UMMC, Baltimore
- Baltimore Washington Medical Center, Glen Burnie · на 9 мили
- Upper Chesapeake Health, Bel Air · на 22 мили
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набиране на участнициФаза 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Набиране на участнициНаблюдателно проучване
- Weinberg Center at Mercy, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- и още 3
Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors
Набиране на участници
- Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Study in Patients With Breast Cancer Leptomeningeal Metastasis
Набиране на участнициНаблюдателно проучване
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · на 8 мили
The Cancer of the Pancreas Screening-5 CAPS5)Study
Набиране на участнициФаза 3
- Johns Hopkins Hospital, Baltimore
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Набиране на участнициФаза 3
- UM Upper Chesapeake Medical Center, Bel Air · на 22 мили
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Набиране на участнициНаблюдателно проучване
- Mercy Medical Center, Baltimore
- Johns Hopkins Hospital, Baltimore
- Luminis Health Center for Cancer & Blood Disorders, Annapolis · на 22 мили
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Набиране на участнициФаза 2
- University of Maryland Medical Center (UMMC), Baltimore
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Набиране на участнициФаза 1/2
- Johns Hopkins, Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Набиране на участнициФаза 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Проучвания за Рак на гърдата в други градове
- New York City, NY136 проучвания
- Houston, TX126 проучвания
- Boston, MA112 проучвания
- Nashville, TN81 проучвания
- Los Angeles, CA73 проучвания
- Edison, NJ68 проучвания
- St. Louis, MO64 проучвания
- Queens, NY64 проучвания
- Durham, NC64 проучвания
- Chicago, IL59 проучвания
- Philadelphia, PA56 проучвания
- Dallas, TX55 проучвания
Други проучвания в Baltimore
- Рак на белия дроб с недребноклетъчен тип60 проучвания
- Рак на простатата43 проучвания
- Рак на белия дроб40 проучвания
- Рак (всички видове)37 проучвания
- Рак на панкреаса31 проучвания
- Колоректален рак31 проучвания
- Метастатичен рак28 проучвания
- Затлъстяване26 проучвания
- Рак на пикочния мехур24 проучвания
- Сърдечна недостатъчност24 проучвания
- Рак на яйчниците22 проучвания
- Инсульт21 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.